Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.